A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)

被引：0
|
作者：
Dumbrava, Ecaterina E.
Kennon, Amber M.
Murthy, Rashmi K.
Montazari, Emma J.
Tawbi, Hussein
Li, Jing
Lang, Frederick F.
Sanchez, Gisela
Wang, Jianbo
Glitza, Isabella C.
O'Brien, Barbara J.
Beckham, Thomas
Swanson, Todd
Tom, Martin C.
Vu, Uyen M.
Darko, Tanisha T.
Cai, Tiantian
Shah, Komal
Meric-Bernstam, Funda
Rodon, Jordi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT289
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [22] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [23] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [24] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Amiri-Kordestani, Laleh
    Blumenthal, Gideon M.
    Xu, Qiang Casey
    Zhang, Lijun
    Tang, Shenghui W.
    Ha, Linan
    Weinberg, Wendy C.
    Chi, Bo
    Candau-Chacon, Reyes
    Hughes, Patricia
    Russell, Anne M.
    Miksinski, Sarah Pope
    Chen, Xiao Hong
    McGuinn, W. David
    Palmby, Todd
    Schrieber, Sarah J.
    Liu, Qi
    Wang, Jian
    Song, Pengfei
    Mehrotra, Nitin
    Skarupa, Lisa
    Clouse, Kathleen
    Al-Hakim, Ali
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4436 - 4441
  • [25] Case series of docetaxel, trastuzumab, and pertuzumab (DTP) and subsequent ado-trastuzumab emtansine (T-DM1) for recurrent or metastatic (R/M) HER2-positive salivary duct carcinoma (SDC)
    Uijen, M.
    Lassche, G.
    van Engen-van Grunsven, A.
    Driessen, C.
    van Herpen, C. M. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S807 - S807
  • [26] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [27] Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] LONG TIME RESPONSE WITH ADO-TRASTUZUMAB EMTANSINE (T-DM1) IN A RECURRENT METASTATIC BREAST CANCER
    Manthri, S.
    Singal, S.
    Youssef, B.
    Chakraborthy, K.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 435 - 435
  • [29] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [30] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
12345